Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Allergenis Inc. manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, indicating a highly focused prosecution stage for the company. A centralized workload like this allows for a consistent and detailed response to office actions, ensuring that the company's technical arguments are fully understood by the examiner. This focus is essential for protecting complex pharmaceutical or biotechnological innovations where claim precision is paramount.
The filing is located in a distinct art unit, which suggests a specialized review process for the company's technology. NGUYEN, BAO THUY L, is the busiest examiner, currently handling the pending office action. This specific interaction will be the primary driver of the company's patent strategy in the near term. Practitioners should focus on building a strong rapport with the examiner and addressing any technical concerns with high-quality evidence to advance the application toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, BAO THUY L | 1 | 41.8% | +22.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18428273 | Assays For Determining Severity Of Peanut Allergies | NGUYEN, BAO THUY L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18428273 | Assays For Determining Severity Of Peanut Allergies | NGUYEN, BAO THUY L | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18428273 | Assays For Determining Severity Of Peanut Allergies | NGUYEN, BAO THUY L | 1677 | §101§103§112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllergenis Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bao Thuy L Nguyen has the most, with 1 of Allergenis Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
